This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: ISTH News

Available Now! Official Highlights Report of ISTH 2013 via MD Conference Express

Monday, August 26, 2013   (0 Comments)
Share |

For an authoritative reference of the key findings from the XXIV Congress of the International Society on Thrombosis and Haemostasis, we invite you to read the official peer-reviewed highlights report.

The top advances from key clinical trials in this report include summaries from AMPLIFY, ACT, and DALTECAN. Feature articles examine the lessons learned from the recent clinical trials that evaluated the novel oral anticoagulant agents, including dabigatran, rivaroxaban, and apixaban; and Mendelian randomization as a promising approach to define which biomarkers are causal for myocardial infarction. Also included are therapeutic updates on advances in the management of von Willebrand disease and hemophilia, prevention of recurrent venous thrombosis, the changing paradigms of new antiplatelet therapy, and hemostatic disorders in women.


For more information about MD Conference Express, please visit:

Membership Management Software Powered by YourMembership  ::  Legal